TEVA PHARMACEUTICAL

Teva’s TEV‑408 hits its Phase 2a primary endpoint, cutting gluten‑induced damage in celiac patients, while a $125M BioXcel deal boosts its biologic pipeline.

Teva’s FDA acceptance of Ecopipam opens a new specialty drug frontier, while patent wins and a Turkish probe test its generics dominance.

Teva’s Q2 2026 earnings show a robust rebound in branded drugs, lifting 2026 outlook and sparking a share surge amid NYSE listing buzz.